# Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation

> **NCT01522651** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 134 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Ranolazine
- **DRUG:** Dronedarone
- **DRUG:** Ranolazine placebo
- **DRUG:** Dronedarone placebo

## Key facts

- **NCT ID:** NCT01522651
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-24
- **Primary completion:** 2014-03-10
- **Final completion:** 2014-03-10
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2020-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01522651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01522651, "Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01522651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*